Saliva test shows promise for earlier and easier detection of mouth and throat cancer

byElsevierAcoustofluidic exosome isolation chip for salivary exosome isolation. The microfluidic channel is shown by red dye solution and the coin demonstrates the size of the chip. Two pairs of

Updated on: December 22,2023 15

Saliva test shows promise for earlier and easier detection of mouth and throat cancer

byElsevierAcoustofluidic exosome isolation chip for salivary exosome isolation. The microfluidic channel is shown by red dye solution and the coin demonstrates the size of the chip. Two pairs of

Updated on:December 22,2023 15

Machine-learning tool to match treatment for cancer patients

byTechnion - Israel Institute of TechnologySummary of pipeline predictions. a An overview of the RNA-MuTect-WMN pipeline: In the training set (n = 100, green arrows), RNA-MuTect is applied on tu

Updated on: December 22,2023 14

Machine-learning tool to match treatment for cancer patients

byTechnion - Israel Institute of TechnologySummary of pipeline predictions. a An overview of the RNA-MuTect-WMN pipeline: In the training set (n = 100, green arrows), RNA-MuTect is applied on tu

Updated on:December 22,2023 14

Survivors of childhood cancer have infection complications years after diagnosis

by Gina Bazer,Northwestern UniversityCredit: Pixabay/CC0 Public DomainInfectious complications continue to affect survivors of childhood cancer many years after initial diagnosis, according to f

Updated on: December 21,2023 10

Survivors of childhood cancer have infection complications years after diagnosis

by Gina Bazer,Northwestern UniversityCredit: Pixabay/CC0 Public DomainInfectious complications continue to affect survivors of childhood cancer many years after initial diagnosis, according to f

Updated on:December 21,2023 10

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

September 30, 2022Ryan ScottThe combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelia

Updated on: October 17,2023 63

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

September 30, 2022Ryan ScottThe combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelia

Updated on:October 17,2023 63

Prexigebersen–Based Therapy Induces High CR/CRi Rates in Newly Diagnosed, Relapsed/Refractory AML

August 1, 2023Caroline SeymourPrexigebersen in combination with decitabine and venetoclax demonstrated potent antitumor activity when used in the treatment of patients with newly diagnosed and relapse

Updated on: October 12,2023 26

Prexigebersen–Based Therapy Induces High CR/CRi Rates in Newly Diagnosed, Relapsed/Refractory AML

August 1, 2023Caroline SeymourPrexigebersen in combination with decitabine and venetoclax demonstrated potent antitumor activity when used in the treatment of patients with newly diagnosed and relapse

Updated on:October 12,2023 26

New antibody shows strong potential as treatment against pancreatic cancer

New antibody shows strong potential as treatment against pancreatic cancerbyTranslational Genomics Research InstituteSIWA318H treatment depletes p16INK4apositive cells and reduces αSMA exp

Updated on: October 30,2023 7

New antibody shows strong potential as treatment against pancreatic cancer

New antibody shows strong potential as treatment against pancreatic cancerbyTranslational Genomics Research InstituteSIWA318H treatment depletes p16INK4apositive cells and reduces αSMA exp

Updated on:October 30,2023 7

B cells linked to effective cancer immunotherapy

by Göran B Jönsson,Lund UniversityImmunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. Credit: Göran

Updated on: December 20,2023 23

B cells linked to effective cancer immunotherapy

by Göran B Jönsson,Lund UniversityImmunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. Credit: Göran

Updated on:December 20,2023 23

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on: December 21,2023 10

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on:December 21,2023 10

suggest better use of existing drugs increases cervical cancer survival and reduces recurrence

byUniversity College LondonCredit: Unsplash/CC0 Public DomainThe INTERLACE phase III trial assessed whether a short course of induction chemotherapy (IC) prior to chemoradiation (CRT) could redu

Updated on: October 23,2023 293

suggest better use of existing drugs increases cervical cancer survival and reduces recurrence

byUniversity College LondonCredit: Unsplash/CC0 Public DomainThe INTERLACE phase III trial assessed whether a short course of induction chemotherapy (IC) prior to chemoradiation (CRT) could redu

Updated on:October 23,2023 293

Universal genetic testing may improve risk stratification and treatment for rare and lethal cancer

Esophageal adenocarcinoma (EAC) is a highly lethal cancer, with a five-year survival rate of less than 20 percent. Although a precursor lesion to EAC, called Barrett's esophagus (BE), is present i

Updated on: November 19,2023 18

Universal genetic testing may improve risk stratification and treatment for rare and lethal cancer

Esophageal adenocarcinoma (EAC) is a highly lethal cancer, with a five-year survival rate of less than 20 percent. Although a precursor lesion to EAC, called Barrett's esophagus (BE), is present i

Updated on:November 19,2023 18

Talazoparib + enzalutamide beneficial in metastatic prostate cancer

by Elana GotkineFor patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according

Updated on: December 17,2023 10

Talazoparib + enzalutamide beneficial in metastatic prostate cancer

by Elana GotkineFor patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according

Updated on:December 17,2023 10

Molecular delivery system developed at URI shows promise against bladder cancer

byUniversity of Rhode IslandpHLIP-ICG can locate cancerous lesions and illuminate them with a fluorescent molecule, making them potentially easier for surgeons to see and remove. Credit: URIA re

Updated on: December 17,2023 9

Molecular delivery system developed at URI shows promise against bladder cancer

byUniversity of Rhode IslandpHLIP-ICG can locate cancerous lesions and illuminate them with a fluorescent molecule, making them potentially easier for surgeons to see and remove. Credit: URIA re

Updated on:December 17,2023 9